Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488468 | 0.87 | OPRM1 (0.60) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL22605862 | 0.86 | CHRM1 (0.57) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL7491969 | 0.86 | HSD11B1 (0.58) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL4152396 | 0.84 | CYP2D6 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL7491573 | 0.84 | OPRM1 (0.64) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL7489071 | 0.84 | OPRM1 (0.65) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL11299007 | 0.84 | OPRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL319049 | 0.83 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL7493374 | 0.83 | OPRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| Hydrochloric Acid SCHEMBL11205630 | 0.83 | CYP2D6 (0.68) | CHRM1CHRM2CHRM4CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | BRADNER JAMES ELLIOT (US) | 2014-07-31 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-8383855-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8304451-B2 | Histone deacetylase and tubulin deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-06 | — | — | US | disclosed |
| US-8222423-B2 | Bifunctional histone deacetylase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-7732438-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| US-20070287697-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | CHRM1 4861/4885CHRM2 4856/4885CHRM4 4884/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | CHRM1 67/4885CHRM2 112/4885CHRM4 461/4885 |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM1 4723/4885CHRM2 4712/4885CHRM4 4800/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM1 4350/4885CHRM2 4368/4885CHRM4 4497/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | CHRM1 4861/4885CHRM2 4856/4885CHRM4 4884/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | CHRM1 4451/4885CHRM2 4722/4885CHRM4 4852/4885 |
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | CHRM1 243/4885CHRM2 305/4885CHRM4 555/4885 |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM1 4723/4885CHRM2 4712/4885CHRM4 4800/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | CHRM1 4050/4885CHRM2 3176/4885CHRM4 4599/4885 |
| US-20070287697-A1 | Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | CHRM1 224/4885CHRM2 169/4885CHRM4 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.